Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Long Venture Downturn, Flagship And Canaan Are In The Money

This article was originally published in The Pink Sheet Daily

Executive Summary

Two veteran life-science venture firms are pushing forward with new funds even as many of their peers can't persuade backers to open their wallets.


Related Content

Third Rock Portfolio Companies Innovate, Sometimes By Returning To The Roots Of Drug Discovery
Third Rock Ventures Rolls Its Own
Merck, GSK, J&J Broaden Strategic LP Relationships, External Discovery Initiatives
Merck Adds Flagship To Its Venture Fund Network
Life Sciences VCs Leave Morgenthaler, ATV To Form New Fund
Advanced BioHealing To Bring Regeneration To Shire


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts